PA
ANTH

Parallel Advisors’s Anthera Pharmaceuticals, Inc. ANTH Stock Holding History

Parallel Advisors’s Portfolio ANTH Stock Details ANTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-104
Closed – – 2199
2017
Q3 		$0 Hold
104
– – ﹤0.01% 2323
2017
Q2 		$0 Buy
104
+91
+700% +$204 ﹤0.01% 2291
2017
Q1 		$0 Buy
+13
New +$61 ﹤0.01% 2137

Other funds holding ANTH

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return

Parallel Advisors's ANTH Position: Q4 2017 in Review

Parallel Advisors sold out of Anthera Pharmaceuticals, Inc. (ANTH) in Q4 2017, closing a stake of 104 shares.

Parallel Advisors first reported a position in ANTH in Q1 2017 and held it in 3 quarters. The position peaked at $0 in Q3 2017. 37 funds tracked by Wall St. Rank hold ANTH as of Q4 2017.

  • Parallel Advisors reported no remaining Anthera Pharmaceuticals, Inc. position as of Q4 2017 after selling out during the quarter.
  • Parallel Advisors sold 104 Anthera Pharmaceuticals, Inc. shares in Q4 2017.
  • Parallel Advisors first reported a position in Anthera Pharmaceuticals, Inc. in Q1 2017 and held it in 3 quarters.
  • Parallel Advisors's Anthera Pharmaceuticals, Inc. position peaked at $0 in Q3 2017.
  • 37 funds tracked by Wall St. Rank held Anthera Pharmaceuticals, Inc. as of Q4 2017.

Based on Parallel Advisors's 13F filing for Q4 2017, filed 13 Feb 2018.